Lilly already had Basaglar, what’s the difference?
It would seem that either the new biosimilar is cheaper to manufacture, or perhaps Lilly and Novo Nordisk are protecting their profit by creating another market level of insulin to try and prop up their huge profits, by executing a multi-tier product strategy.
So we have Basaglar and Semglee, now this?
Rezvolgar (which shows no results whatsoever on DuckDuckGo as of this moment) is an insulin resplundent with the mythology of the Norse Gods, without the clear suggestions of vomiting called to forth by the previous speeling (RezVoglar), anyway, someone of little merit had already trademarked it.
Marketing experts, well, they told me they were, determined (apparently anabiotically) that my new name was far more appropriate for the modern insulin consuming marketplace. Who am I to believe otherwise?
Basaglar is not a biosimilar for legal reasons.